GlassScriptPhysician profile
Edgar A Figueroa
NPI 1487650883
$1,373.59
in general payments reported to CMS, 2019-2025
20 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $71.19 · 2021: $253 · 2022: $198 · 2023: $307 · 2024: $297 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $282.98 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $254.97 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $187.99 | 2020-2023 | |
| Pfizer INC. | $107.87 | 2020-2025 | |
| Glaxosmithkline, LLC. | $99.71 | 2020-2024 | Trelegy Ellipta |
| Amgen INC. | $57.30 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $51.48 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.80 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $32.31 | 2019-2021 | |
| Si-Bone, INC. | $31.85 | 2022 | |
| Lilly USA, LLC | $28.86 | 2023 | Emgality, Jardiance |
| Nevro Corp. | $28.19 | 2023 | Senza |
| Ultragenyx Pharmaceutical INC. | $27.22 | 2022 | |
| Corcept Therapeutics | $27.16 | 2023 | Korlym |
| Medicomp INC | $25.32 | 2024 | Telepatch Cardiac Monitor |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $23.09 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.81 | 2025 | Jardiance |
| Sunovion Pharmaceuticals INC. | $15.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.90 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Figueroa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.